Description:
Galeterone (TOK-001 or VN/124-1) is a novel antiandrogen under development by Tokai Pharmaceuticals for the treatment of prostate cancer. It possesses a unique dual mechanism of action, acting as both anandrogen receptor antagonist and an inhibitor of CYP17A1, an enzyme required for the biosynthesis of theandrogens.
- Molecular Weight: 388.555
- Molecular Formula: C26H32N2O
Purity: >98%
Canonical SMILES:
CC12CCC(CC1=CCC3C2CCC4(C3CC=C4N5C=NC6=CC=CC=C65)C)O
InChI:
InChI=1S/C26H32N2O/c1-25-13-11-18(29)15-17(25)7-8-19-20-9-10-24(26(20,2)14-12-21(19)25)28-16-27-22-5-3-4-6-23(22)28/h3-7,10,16,18-21,29H,8-9,11-15H2,1-2H3/t18-,19-,20-,21-,25-,26-/m0/s1
InChIKey: PAFKTGFSEFKSQG-PAASFTFBSA-N
Synonyms:
TOK-001; TOK 001; TOK001; NX41765; NX 41765; NX-41765; VN 124; VN124; VN-124; VN/124-1; (3S,8R,9S,10R,13S,14S)-17-(benzimidazol-1-yl)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol
More details are to be found on supplier website
